Until the early 20th century, the human life expectancy was less than 50 years, and infections were often fatal. Only in the past century have humans, on average, lived long enough for cardiovascular ...
Empagliflozin improves cardiovascular outcomes in patients with heart failure, patients with type 2 diabetes who are at high cardiovascular risk, and patients with chronic kidney disease. The safety ...
Myocardial infarction (MI) causes millions of deaths worldwide. Though there have been advances in the survival rates following ST-elevation MI (STEMI), survivors often develop heart failure due to ...
Credit: Getty Images. A discussion of the use of beta-blocker therapy following AMI, with Christopher Granger, MD, Gregg Fonarow, MD, and Carlin S Long, MD. The role of beta-blockers after acute ...
Advanced CKD in AMI patients receiving MCS is associated with increased mortality, complications, and resource utilization compared to those without advanced CKD. ESRD patients undergoing CABG after ...
Empagliflozin stabilizes kidney function and reduces heart failure risk post-myocardial infarction, with eGFR remaining stable over 24 months. The EMPACT-MI trial confirmed empagliflozin's safety when ...
Researchers conducted an observational study using data from a Danish cohort (1993-1997; age range, 50-64 years). Overall, 5816 participants with newly diagnosed atrial fibrillation only, 3448 with ...
Some results have been hidden because they may be inaccessible to you
Show inaccessible results